Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Further Analysis Confirms Usefulness of SGN-36: Takeda
June 27, 2011
- Korosho to Invite Requests for Development of Unapproved Drugs/Applications in August
June 27, 2011
- Council Approves Basic Policy for Promotion of Medical Innovation
June 27, 2011
- Roche Confirms Efficacy of Actemra Monotherapy
June 27, 2011
- GenomIdea Ties Up with TSD Japan for Licensing HVJ-E
June 27, 2011
- Korosho to Create ICH GCP-Compliant “Clinical Research Core Hospitals”
June 27, 2011
- Miraka HD: Sales Up 11.2% with Addition of New Subsidiaries
June 27, 2011
- Bayer to Strengthen Its PV Division
June 20, 2011
- FDA Approves pNET as Additional Indication for Sutent: Pfizer
June 20, 2011
- Axitinib Increases PFS Compared to Sorafenib in Previously Treated RCC Patients: ASCO
June 20, 2011
- Bayer to Accumulate Medicoeconomic Evidence
June 20, 2011
- MediBIC: Glufosfamide Granted Orphan Drug Status in Europe
June 20, 2011
- Korosho to Preferentially Support High-Quality Clinical Research
June 20, 2011
- ASKA Spreading Risks in Production, Distribution to Ensure Stable Supplies
June 20, 2011
- Korosho Calls For Development of 3 Drugs Used Off-label
June 20, 2011
- Reform Council Sees ¥1.6 Tril. Increase in Healthcare/Nursing Expenditure in FY2015
June 20, 2011
- Top-3 Dispensing Pharmacy Chains Report Record-high Sales, Profits Driven by New Store Openings
June 20, 2011
- Infections Added as Serious ADE for Revlimid: Safety Info.
June 20, 2011
- Korosho's Expert Committee Proposes Creation of “Pediatric Cancer Hub Hospitals”
June 20, 2011
- Major Drugstore Chains Report Increased Sales in Dispensing Business
June 20, 2011
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…